Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | METAP2 | P50579 | 15/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | MET | P08581 | 1/20 | 0.38 |
| ▸ | HDAC1 | Q13547 | 3/20 | 0.38 |
| ▸ | HDAC8 | Q9BY41 | 3/20 | 0.38 |
| ▸ | HDAC6 | Q9UBN7 | 3/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12561586 | 1.00 | METAP2 (0.44) | METAP2LMNAMETHDAC1HDAC8 | |
| SCHEMBL12411801 | 0.92 | LMNA (0.44) | METAP2LMNAMETHDAC1 | |
| SCHEMBL12561299 | 0.92 | LMNA (0.44) | METAP2LMNAMETHDAC1 | |
| SCHEMBL12561298 | 0.92 | LMNA (0.44) | METAP2LMNAMETHDAC1 | |
| SCHEMBL14817519 | 0.86 | METAP2 (0.51) | METAP2METHDAC8HDAC6 | |
| SCHEMBL12536319 | 0.85 | METAP2 (0.41) | METAP2LMNAMET | |
| SCHEMBL12376625 | 0.85 | METAP2 (0.41) | METAP2LMNAMET | |
| SCHEMBL12536318 | 0.85 | METAP2 (0.41) | METAP2LMNAMET | |
| SCHEMBL14411704 | 0.85 | METAP2 (0.46) | METAP2LMNA | |
| SCHEMBL12561596 | 0.85 | METAP2 (0.46) | METAP2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110053931-A1 | QUINOLINE COMPOUNDS AND METHODS OF USE | GAUDINO JOHN | 2011-03-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110053931-A1 | QUINOLINE COMPOUNDS AND METHODS OF USE | TK1, ABL1, ROR1 | METAP2 2958/4885LMNA 1139/4885MET 563/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.